Home › Research › Getting a diagnosis
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease
Janelidze S, Janelidze S, Bali D, Ashton NJ, Barthélemy NR, Vanbrabant J, Stoops E, Vanmechelen E et al.. Brain : a journal of neurology, 2023-04-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
We found that the mass spectrometry-based p-tau217 (p-tau217WashU) exhibited significantly better performance than all other plasma p-tau biomarkers when detecting abnormal Aβ status [area under curve (AUC) = 0.947; Pdiff 0.09), but higher compared with AUC of p-tau231UGOT, p-tau181Lilly, p-tau181UGOT, p-tau181Fuji and p-tau181Splex (AUCrange 0.642-0.813; Pdiff ≤ 0.029). Correlations between plasma and CSF values were strongest for p-tau217WashU (R = 0.891) followed by p-tau217Lilly (R = 0.755; Pdiff = 0.003 versus p-tau217WashU) and weak to moderate for the rest of the p-tau biomarkers (Rrange 0.320-0.669). In conclusion, our findings suggest that among all tested plasma p-tau assays, mass spectrometry-based measures of p-tau217 perform best when identifying mild cognitive impairment patients with abnormal brain Aβ or those who will subsequently progress to Alzheimer's dementia. The results further indicate that the highest performing assays have performance metrics that rival the gold standards of Aβ-PET and CSF. If further validated, our findings will have significant impacts in diagnosis, screening and treatment for Alzheimer's dementia in the future.
What this study adds
Evidence grade: Low
The record lists 135 participants. This study compared several blood tests for the protein p-tau in people with mild cognitive impairment. Reported effect size: 60.7%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Janelidze, S., Bali, D., Ashton, N. J., Barthélemy, N. R., Vanbrabant, J., Stoops, E., et al. (2023). Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease. Brain : a journal of neurology. https://doi.org/10.1093/brain/awac333
Vancouver
Janelidze S, Bali D, Ashton NJ, Barthélemy NR, Vanbrabant J, Stoops E, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease. Brain : a journal of neurology. 2023. doi:10.1093/brain/awac333. PMID: 36087307.
BibTeX
@article{janelidze2023-36087307,
author = {Janelidze, S. and Bali, D. and Ashton, N. J. and Barthélemy, N. R. and Vanbrabant, J. and Stoops, E. and Vanmechelen, E. and others},
title = {{Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease}},
journal = {Brain : a journal of neurology},
year = {2023},
doi = {10.1093/brain/awac333},
pmid = {36087307},
url = {https://doi.org/10.1093/brain/awac333}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We found that the mass spectrometry-based p-tau217 (p-tau217WashU) exhibited significantly better performance than all other plasma p-tau biomarkers when detecting abnormal Aβ status [area under curve (AUC) = 0.947; Pdiff < 0.015] or progression to Alzheimer's dementia (AUC = 0.932; Pdiff < 0.027).
- Correlations between plasma and CSF values were strongest for p-tau217WashU (R = 0.891) followed by p-tau217Lilly (R = 0.755; Pdiff = 0.003 versus p-tau217WashU) and weak to moderate for the rest of the p-tau biomarkers (Rrange 0.320-0.669).
- In conclusion, our findings suggest that among all tested plasma p-tau assays, mass spectrometry-based measures of p-tau217 perform best when identifying mild cognitive impairment patients with abnormal brain Aβ or those who will subsequently progress to Alzheimer's dementia.
- The results further indicate that the highest performing assays have performance metrics that rival the gold standards of Aβ-PET and CSF.
- If further validated, our findings will have significant impacts in diagnosis, screening and treatment for Alzheimer's dementia in the future.
Why it matters
This study compared several blood tests for the protein p-tau in people with mild cognitive impairment. A mass-spectrometry p-tau217 test was best at spotting people with amyloid in the brain (AUC 0.947, against 0.642–0.813 for five other assays) and matched spinal-fluid levels most closely (R = 0.891, against 0.755 for a second p-tau217 test). The authors say the best tests "rival the gold standards of Aβ-PET and CSF" but that the findings need further validation, so it does not establish any blood test as a stand-alone diagnosis.
New to this subject? Start with our plain-English guide: Getting a diagnosis →
Study details
- Participants135
- Effect size60.7%
- Evidence strengthLow
How this study scored 72/100
Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Brain : a journal of neurology) |
| Journal's citation record | 4 / 4 | Brain: journal h-index 503 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 135 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 517 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 103.4 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 6 / 6 | Cited 59.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 66 other studies in this library |
| Still being cited | 4 / 4 | Cited 441 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Oskar Hansson: h-index 148 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 17 institution(s) in 5 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36087307) |
| Free to read | 2 / 2 | Free to read |
| Total | 72 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 17.
Later studies that cite this one
66 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Getting a diagnosis from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.